| Literature DB >> 20434550 |
Gili Regev-Yochay1, William P Hanage, Krzysztof Trzcinski, Sheryl L Rifas-Shiman, Grace Lee, Andrew Bessolo, Susan S Huang, Stephen I Pelton, Alexander J McAdam, Jonathan A Finkelstein, Marc Lipsitch, Richard Malley.
Abstract
Pneumococcal type 1 pilus proteins have been proposed as potential vaccine candidates. Following conjugate pneumococcal vaccination, the prevalence of the pneumococcal type 1 pilus declined dramatically, a decline associated with the elimination of vaccine-type (VT) strains. Here we show that between 2004 and 2007, there has been a significant increase in pilus prevalence, now exceeding rates from the pre-conjugate vaccine era. This increase is primarily due to non-VT strains. These emerging piliated non-VT strains are mostly novel clones, with some exceptions. The rise in pilus type 1 frequency across multiple distinct genetic backgrounds suggests that the pilus may confer an intrinsic advantage. Copyright 2010 Elsevier Ltd. All rights reserved.Entities:
Mesh：
Substances：
Year: 2010 PMID： 20434550 PMCID： PMC2897942 DOI： 10.1016/j.vaccine.2010.04.042
Source DB: PubMed Journal: Vaccine ISSN： 0264-410X Impact factor: 3.641